Pregabalin Capsule
Product Images NDC 70518-4272

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-4272). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Pregabalin 25 mg oral capsules packaging label from RemedyRepack Inc. The label indicates a supply of 30 capsules. It includes prescription-only status, NDC number 70518-4272-00, and notes the original manufacturer as Camber Pharma, Inc. Directions refer users to the package insert, with storage temperature recommendations between 20-25°C and permitted excursions from 15-30°C.*

FDA Label Image

Pregabalinfigure1 (Pregabalinfigure1)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 25 mg, 100 mg, and 200 mg three times a day compared to placebo. The curves illustrate higher improvement with increasing Pregabalin doses relative to placebo.*

FDA Label Image

Pregabalinfigure10 (Pregabalinfigure10)

A survival curve chart showing estimated percentage of subjects without LTR over 180 days. Two lines compare Pregabalin and placebo groups, with the Pregabalin group showing a higher estimated percentage without LTR over time.*

FDA Label Image

Pregabalinfigure11 (Pregabalinfigure11)

A line graph comparing the percent of subjects improved over time from baseline to Week 12 BOCF for Pregabalin and Placebo groups. The y-axis shows percent of subjects improved, while the x-axis shows the percent improved from baseline to Week 12 BOCF, with Pregabalin consistently showing higher improvement than Placebo.*

FDA Label Image

Pregabalinfigure12 (Pregabalinfigure12)

A line graph comparing percent of subjects improved over time between Pregabalin and placebo groups. The x-axis shows percent improved from baseline to week 16 BOCF, and the y-axis shows percent of subjects improved from 0% to 100%. Pregabalin consistently shows higher improvement rates than placebo throughout the period.*

FDA Label Image

Pregabalinfigure2 (Pregabalinfigure2)

A line chart comparing the percent improvement in pain from baseline to percent of patients improved. The chart includes two lines representing Pregabalin 100 mg administered three times a day and a placebo. The x-axis shows percent improvement in pain from baseline, while the y-axis shows the percent of patients improved.*

FDA Label Image

Pregabalinfigure3 (Pregabalinfigure3)

A line graph illustrating percent of patients improved versus percent improvement in pain from baseline. The graph compares placebo with three dosages of Pregabalin (75 mg, 150 mg, and 300 mg, all taken twice a day), showing trends in patient improvement across these groups.*

FDA Label Image

Pregabalinfigure4 (Pregabalinfigure4)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph illustrates pain improvement across these treatments over increasing percent improvement intervals.*

FDA Label Image

Pregabalinfigure5 (Pregabalinfigure5)

A line graph showing the percent improvement in pain from baseline on the x-axis and the percent of patients improved on the y-axis. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating their relative effectiveness in pain improvement.*

FDA Label Image

Pregabalinfigure6 (Pregabalinfigure6)

A bar graph comparing responder rates (%) in two studies, E1 and E3, across different doses including placebo, 150 mg/day, 600 mg/day, and 900 mg/day for Study E1, and placebo, 600 mg/day, and 750 mg/day for Study E3. The graph shows higher responder rates with increasing doses and notes statistical significance versus placebo where applicable.*

FDA Label Image

Pregabalinfigure7 (Pregabalinfigure7)

A dose-response line graph showing median percentage reduction in seizures from baseline plotted against Pregabalin dose in mg/day. Four dose groups from Study E1 and E3 are illustrated with different symbols representing BID and TID dosing schedules, each showing increasing seizure reduction with higher doses.*

FDA Label Image

Pregabalinfigure8 (Pregabalinfigure8)

A bar graph depicting responder rates (%) for three groups: Placebo (22.6%), 2.5 mg/kg/day (29.1%), and 10 mg/kg/day (40.6%). The x-axis lists the groups with sample sizes (Placebo = 93, 2.5 mg/kg/day = 103, 10 mg/kg/day = 96), and the y-axis shows responder rate percentage from 0 to 60%.*

FDA Label Image

Pregabalinfigure9 (Pregabalinfigure9)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 600 mg, 450 mg, 300 mg daily, and placebo. The graph shows decreasing patient improvement percentages as pain improvement percentage increases, with separate lines representing each dose and placebo over the range 0 to 100 percent improvement.*

FDA Label Image

Pregabalinstructure (Pregabalinstructure)

Chemical structure of Pregabalin, a human prescription drug capsule with oral route, showing its molecular composition including amino, methyl, and carboxyl groups as displayed in the structure diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.